165 related articles for article (PubMed ID: 20068112)
1. The cross-validated adaptive signature design.
Freidlin B; Jiang W; Simon R
Clin Cancer Res; 2010 Jan; 16(2):691-8. PubMed ID: 20068112
[TBL] [Abstract][Full Text] [Related]
2. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients.
Freidlin B; Simon R
Clin Cancer Res; 2005 Nov; 11(21):7872-8. PubMed ID: 16278411
[TBL] [Abstract][Full Text] [Related]
3. Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect.
Jiang W; Freidlin B; Simon R
J Natl Cancer Inst; 2007 Jul; 99(13):1036-43. PubMed ID: 17596577
[TBL] [Abstract][Full Text] [Related]
4. Improving the design of phase II trials of cytostatic anticancer agents.
Stone A; Wheeler C; Barge A
Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
[TBL] [Abstract][Full Text] [Related]
5. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer.
Straver ME; Glas AM; Hannemann J; Wesseling J; van de Vijver MJ; Rutgers EJ; Vrancken Peeters MJ; van Tinteren H; Van't Veer LJ; Rodenhuis S
Breast Cancer Res Treat; 2010 Feb; 119(3):551-8. PubMed ID: 19214742
[TBL] [Abstract][Full Text] [Related]
6. Clinical trial design in metastatic breast cancer: a commentary.
Levine M
Can J Oncol; 1995 Dec; 5 Suppl 1():40-2. PubMed ID: 8853523
[TBL] [Abstract][Full Text] [Related]
7. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
[TBL] [Abstract][Full Text] [Related]
8. On the efficiency of targeted clinical trials.
Maitournam A; Simon R
Stat Med; 2005 Feb; 24(3):329-39. PubMed ID: 15551403
[TBL] [Abstract][Full Text] [Related]
9. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
10. Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention.
Kaye SB
Curr Opin Oncol; 1998 Aug; 10 Suppl 1():S15-9. PubMed ID: 9801854
[TBL] [Abstract][Full Text] [Related]
11. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
Berry J
Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
[TBL] [Abstract][Full Text] [Related]
12. Drug resistance in chemotherapy for breast cancer.
Saeki T; Tsuruo T; Sato W; Nishikawsa K
Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():84-9. PubMed ID: 16273361
[TBL] [Abstract][Full Text] [Related]
13. The Challenge of Developing New Therapies for Childhood Cancers.
Balis FM
Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
[TBL] [Abstract][Full Text] [Related]
14. Optimal sequence of anthracyclines and taxanes as adjuvant breast cancer treatment.
Vici P; Viola G; Rossi S; Botti C; Vitucci C; Sergi D; Ferranti FR; Saracca E; Di Lauro L; Corsetti S; Foggi P; Fattoruso SI; Lopez M
Clin Ter; 2008; 159(6):453-6. PubMed ID: 19169608
[TBL] [Abstract][Full Text] [Related]
15. Multi-arm clinical trials of new agents: some design considerations.
Freidlin B; Korn EL; Gray R; Martin A
Clin Cancer Res; 2008 Jul; 14(14):4368-71. PubMed ID: 18628449
[TBL] [Abstract][Full Text] [Related]
16. Fit-for-purpose biomarker method validation in anticancer drug development.
Cummings J; Ward TH; Dive C
Drug Discov Today; 2010 Oct; 15(19-20):816-25. PubMed ID: 20708097
[TBL] [Abstract][Full Text] [Related]
17. Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends.
Moreno-Aspitia A; Perez EA
Clin Ther; 2009 Aug; 31(8):1619-40. PubMed ID: 19808124
[TBL] [Abstract][Full Text] [Related]
18. Development of the 21-gene assay and its application in clinical practice and clinical trials.
Sparano JA; Paik S
J Clin Oncol; 2008 Feb; 26(5):721-8. PubMed ID: 18258979
[TBL] [Abstract][Full Text] [Related]
19. Adaptive designs for confirmatory clinical trials.
Bretz F; Koenig F; Brannath W; Glimm E; Posch M
Stat Med; 2009 Apr; 28(8):1181-217. PubMed ID: 19206095
[TBL] [Abstract][Full Text] [Related]
20. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]